ArticleBiology direct2026
Comprehensive pan-cancer analysis reveals SH3GLB1 is a novel prognostic biomarker with immunomodulatory potential.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BIF-1 expression in human cancers: roles in apoptosis, autophagy, and therapeutic potential.European biophysics journal : EBJ · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer continues to represent a significant global health challenge, underscoring the urgent need for novel biomarkers to enhance early diagnosis and prognosis prediction. SH3 domain-containing GRB2-like B1 (SH3GLB1), also known as Bax interaction factor 1 (BIF-1), is a key regulator of apoptosis, autophagy, and endocytosis. However, its role across various cancer types remains insufficiently characterized.
methodsWe performed an integrated multi-omics analysi to assess the diagnostic and prognostic potential of SH3GLB1 across 33 cancer types, encompassing expression profiling at both mRNA and protein levels, genomic alterations, interactions with the immune microenvironment, and functional enrichment pathways. The finding was validated in Colorectal Cancer (CRC), both in vitro and in vivo.
resultsSH3GLB1 expression was significantly downregulated in the majority of tumor types examined, at both mRNA and protein levels. Low SH3GLB1 expression was associated with poorer overall survival in CRC and several other cancers. Besides, SH3GLB1 was correlated with immune-inflamed tumor microenvironments, characterized by increased infiltration of CD8 + T cells and dendritic cells. Functional analyses revealed that SH3GLB1 loss activated RAS-MAPK and EMT signaling pathways, and experimental models confirmed its role in promoting CRC cell proliferation, migration in vitro, and tumor growth in vivo.
conclusionSH3GLB1 exhibits significant diversity and complexity in its tumor-suppressive functions, highlighting its potential as a promising biomarker and therapeutic target for improving the efficacy of cancer treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.